NCT03582449View on ClinicalTrials.gov

Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)

CompletedOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

January 19, 2018

Primary Completion Date

May 10, 2020

Study Completion Date

May 10, 2020

Conditions
Hunter Syndrome
Trial Locations (6)

28019

Hospital Universitario de Colima, Colima

64180

IMSS UMAE 25 (INSTITUTO MEXICANO DEL SEGURO SOCIAL UNIDAD MEDICA DE ALTA ESPECIALIDAD No 25), Monterrey

80200

Hospital Pediátrico de Sinaloa, Culiacán Rosales

86100

Hospital del Niño Tabasqueño, Villahermosa

CP 20000

Hospital Centenario Miguel Hidalgo, Aguascalientes

06720

Hospital Infantil Federico Gomez, Mexico City

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT03582449 - Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701) | Biotech Hunter | Biotech Hunter